SPATA31 subfamily E member 1Genealiases: C9orf79 · FAM75E1
Q-omics provides the consensus-scored SPATA31E1 profile across patient tissues and cancer cell-line models. SPATA31E1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SPATA31E1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, SPATA31E1 RNA expression shows 10,297 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, COAD, and TGCT as cancer lineages where SPATA31E1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA31E1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA31E1 survival associations across molecular data types. SPATA31E1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA31E1 RNA expression–survival associations across cancer types. High SPATA31E1 expression shows unfavorable associations in ACC, LIHC, MESO and LUSC, but favorable associations in BLCA and GBM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify BLCA as the clearest survival context for SPATA31E1 RNA expression.
This table summarizes SPATA31E1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA31E1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA31E1 shows lower tumor expression in COAD, BLCA and READ and higher tumor expression in KIRC, PRAD and LIHC. The COAD box plot shows higher SPATA31E1 RNA expression in normal versus tumor tissue (log2 FC = −0.058, t-test p < 0.001).
This table shows molecular features associated with SPATA31E1 in patient tissues and cancer cell lines. In patient samples, SPATA31E1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA31E1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
